WO2002059606A3 - Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv - Google Patents
Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv Download PDFInfo
- Publication number
- WO2002059606A3 WO2002059606A3 PCT/EP2002/000659 EP0200659W WO02059606A3 WO 2002059606 A3 WO2002059606 A3 WO 2002059606A3 EP 0200659 W EP0200659 W EP 0200659W WO 02059606 A3 WO02059606 A3 WO 02059606A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatmnt
- epstein
- targets
- therapeutic agents
- virus infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/05—Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002237287A AU2002237287A1 (en) | 2001-01-23 | 2002-01-23 | Targets and therapeutic agents for the treatmnt of epstein-barr virus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01101452.9 | 2001-01-23 | ||
EP01101452 | 2001-01-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002059606A2 WO2002059606A2 (fr) | 2002-08-01 |
WO2002059606A3 true WO2002059606A3 (fr) | 2003-10-16 |
Family
ID=8176276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/000659 WO2002059606A2 (fr) | 2001-01-23 | 2002-01-23 | Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002237287A1 (fr) |
WO (1) | WO2002059606A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102660469A (zh) * | 2012-05-31 | 2012-09-12 | 哈尔滨工业大学 | 一种表达植物抗性诱导因子的毕赤酵母基因工程菌株的构建方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032307A1 (fr) * | 1994-05-20 | 1995-11-30 | Tularik, Inc. | Procede d'immunodetection du facteur de transcription du virus d'epstein-barr |
WO1996020723A1 (fr) * | 1994-12-30 | 1996-07-11 | Brigham & Women's Hospital | Regulation de signaux induits par traf |
US6162440A (en) * | 1996-02-13 | 2000-12-19 | Johns Hopkins University School Of Medicine | EBNA2 peptides and methods of using same |
-
2002
- 2002-01-23 WO PCT/EP2002/000659 patent/WO2002059606A2/fr not_active Application Discontinuation
- 2002-01-23 AU AU2002237287A patent/AU2002237287A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032307A1 (fr) * | 1994-05-20 | 1995-11-30 | Tularik, Inc. | Procede d'immunodetection du facteur de transcription du virus d'epstein-barr |
WO1996020723A1 (fr) * | 1994-12-30 | 1996-07-11 | Brigham & Women's Hospital | Regulation de signaux induits par traf |
US6162440A (en) * | 1996-02-13 | 2000-12-19 | Johns Hopkins University School Of Medicine | EBNA2 peptides and methods of using same |
Non-Patent Citations (1)
Title |
---|
KAISER CARMEN ET AL: "Functional genomics in cancer research: Identification of target genes of the Epstein-Barr virus nuclear antigen 2 by subtractive cDNA cloning and high-throughput differential screening using high-density agarose gels.", ELECTROPHORESIS, vol. 20, no. 2, February 1999 (1999-02-01), pages 261 - 268, XP002232293, ISSN: 0173-0835 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002237287A1 (en) | 2002-08-06 |
WO2002059606A2 (fr) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1041521A1 (en) | Growth differentiation factor inhibitors and uses therefor | |
ATE401079T1 (de) | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen | |
DE60138549D1 (de) | Topische gel-abgabesysteme zur behandlung von hauterkrankungen | |
ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
WO2004006853A3 (fr) | Traitement et prevention a l'aide d'agents fixant 4-1bb | |
WO2003024386A8 (fr) | Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse | |
WO2003002108A3 (fr) | Utilisation d'inhibiteurs de tyrosine kinase destines au traitement de maladies inflammatoires | |
GB0130677D0 (en) | Medicaments and novel compounds | |
WO2003002107A3 (fr) | Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques | |
WO2003002105A3 (fr) | Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse | |
WO2003004006A8 (fr) | Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale | |
WO2004004653A3 (fr) | Methodes de traitement de la psychose associee a une therapie aux interferon $g(a) | |
WO2004098612A3 (fr) | Nouveaux analogues de calcitriol et leur utilisation | |
WO2002059606A3 (fr) | Nouvelles cibles et nouveaux agents therapeutiques pour le traitement de l'infection a ebv | |
WO2004037192A3 (fr) | Identification et inhibition de cibles anti-mycobacteriennes pour le traitement de maladies infectieuses | |
ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
WO2001083754A3 (fr) | Regulateurs cellulaires d'agents infectieux et methodes d'utilisations | |
WO2003103699A8 (fr) | Utilisation de ramoplanine pour traiter des troubles associes a la prise d'antibiotiques | |
DE60223564D1 (de) | Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren | |
WO2004087067A3 (fr) | Traitement d'infections par aspergillus a l'aide de thymosine alpha 1 | |
DE60020833D1 (de) | Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag | |
AU2900100A (en) | Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss | |
WO2003030936A1 (fr) | Medicaments contre des maladies liees au style de vie ou la cibophobie et methode de criblage de ces derniers | |
AU2003250248A1 (en) | Process and auxiliaries for the treatment of organically tanned leather | |
DE60030724D1 (en) | Tryptaseninhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |